Pyrazolo[1,5-A]pyrazin-4-yl and related derivatives
A compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein variables are defined in the specification. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.
1. A compound having the structure:
or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein:
W is H, halo, or is selected from the group consisting of:
A, A′ and A″ are independently O, S, C═O, C—R′, N or N—R″, where R′ and R″ may independently be H, amino, —NR 7 COR 6 , COR 6 , —CONR 7 R 8 , —NHSO 2 (C 1 -C 6 alkyl), C 1 -C 6 alkyl, halo, amino(C 1 -C 6 alkyl)-, C 3 -C 8 cycloalkyl, heteroaryl, heterocyclic, heterocyclic(C 1 -C 6 alk-yl)-, hydroxy(C 1 -C 6 alkyl)-, or hydroxy(halo-C 1 -C 6 alkyl)-, where each said moiety may be present or absent, and is present where the rules of valency permit, subject to the proviso that not more than one of A, A′ and A″ is O, S or C═O; where C 1 -C 6 alkyl is optionally substituted by OH, halo, N(C 1 -C 6 alkyl) and heterocyclic;
R 0 is H, D or C 1 -C 6 alkyl-;
Y, Z, and Z′ are independently C—R 1 , or N, where R 1 is H, halo, amino, —NR 7 COR 6 , COR 6 , —CONR 7 R 8 , —NHSO 2 (C 1 -C 6 alkyl), C 1 -C 6 alkyl, halo, amino(C 1 -C 6 alkyl)- or hydroxy(C 1 -C 6 alkyl)-;
Y′ is O, C—R 1 or N, where R 1 is H, halo, amino, —NR 7 COR 6 , COR 6 , —CONR 7 R 8 , —NHSO 2 (C 1 -C 6 alkyl), C 1 -C 6 alkyl, halo, amino(C 1 -C 6 alkyl)- or hydroxy(C 1 -C 6 alkyl)-;
Q is CN or CONH 2 ;
R 2 is selected from the group consisting of H, C 1 -C 6 alkyl-, C 1 -C 6 alkoxy-, hydroxy(C 1 -C 6 alkyl)-, phenyl(C 1 -C 6 alkyl)-, C 3 -C 8 cycloalkyl, halo(C 3 -C 8 cycloalkyl), spirocyclic, formyl, heteroaryl, heterocyclic, —COR, —OCOR, —COOR, —NR 7 COR, CONR 7 R 8 , and —(CH 2 ) n —W′, where W′ is cyano, hydroxy, C 3 -C 8 cycloalkyl, —SO 2 NR 7 R 8 , and —SO 2 -R 9 , where R 9 is C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, heteroaryl, or heterocyclic; wherein each of said alkyl, cycloalkyl, heterocyclic, or heteroaryl may be unsubstituted or substituted by halo, cyano, hydroxy, or C 1 -C 6 alkyl; or, R 2 and R 3 when taken together forms a C 3 -C 8 cycloalkyl group or C 4 -C 8 heterocyclic group; wherein heterocyclic or heteroaryl group may be substituted by C 1 -C 6 alkyl, halo or hydroxy;
X is C—R 3 or N, where R 3 may be H or C 1 -C 6 alkyl;
R 4 , R 5 and R 6 are independently H, halo, amino, —OH, —CO 2 H, —CONH 2 , C 1 -C 6 alkyl, C 1 -C 6 alkoxy-, —hydroxy(C 1 -C 6 alkoxy)-, hydroxy(C 1 -C 6 alkoxy)-, heteroaryl-, heterocyclic-, —SO 2 NH 2 , —NHSO 2 (C 1 -C 6 alkyl), —NHCO(C 1 -C 6 alkyl), —NHCO 2 (C 1 -C 6 alkyl), —SO 2 (C 1 -C 6 alkyl), amino(C 1 -C 6 alkoxy), amino(C 1 -C 6 alkyl)- or hydroxy(C 1 -C 6 alkyl)-;
R, R 7 and R 8 are each independently H, C 1 -C 6 alkyl, C 1 -C 4 alkoxy(C 1 -C 6 alkyl) or C 3 -C 8 cycloalkyl, said C 1 -C 6 alkyl is optionally substituted by halo, CN or hydroxy; or, R 7 and R 8 together with the atom bonded thereto form a 5- or 6-membered ring, said ring being optionally substituted by halo, hydroxy, CN, or C 1 -C 6 alkyl; and,
n is 0, 1, 2 or 3.
2. The compound of claim 1 wherein X is C.
3. The compound of claim 1 wherein R 2 is CN and R 4 is H.
4. The compound of claim 1 wherein Y is CH or N.
5. The compound of claim 1 wherein Z is N and Z′ is CH.
6. The compound of claim 1 having the structure (Ia):
or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein:
A, A′ and A″ are independently O, S, C═O, C—R′, N or N—R″, where R′ and R″ may independently be H, amino, —NR 7 COR 6 , COR 6 , —CONR 7 R 8 , —NHSO 2 (C 1 -C 6 alkyl), C 1 -C 6 alkyl, halo, amino(C 1 -C 6 alkyl)-, C 3 -C 8 cycloalkyl, heteroaryl, heterocyclic, heterocyclic(C 1 -C 6 alk-yl)-, hydroxy(C 1 -C 6 alkyl)-, or hydroxy(halo-C 1 -C 6 alkyl)-, where each said moiety may be present or absent, and is present where the rules of valency permit, subject to the proviso that not more than one of A, A′ and A″ is O, S or C═O; where C 1 -C 6 alkyl is optionally substituted by OH, halo, N(C 1 -C 6 alkyl) and heterocyclic;
R 0 is H, D or C 1 -C 6 alkyl-;
Z is C—R 1 or N, where R 1 is H, halo, amino, —NR 7 COR 6 , COR 6 , —CONR 7 R 8 , —NHSO 2 (C 1 -C 6 alkyl), C 1 -C 6 alkyl, halo, amino(C 1 -C 6 alkyl)- or hydroxy(C 1 -C 6 alkyl)-; Z″ and Z″′ are independently C—R′ or N—R″;
R 5 and R 6 are independently H, halo, amino, —OH, —CO 2 H, —CONH 2 , C 1 -C 6 alkyl, C 1 -C 6 alkoxy-, —hydroxy(C 1 -C 6 alkoxy)-, hydroxy(C 1 -C 6 alkoxy)-, heteroaryl-, heterocyclic-, —SO 2 NH 2 , —NHSO 2 (C 1 -C 6 alkyl), —NHCO(C 1 -C 6 alkyl), —NHCO 2 (C 1 -C 6 alkyl), —SO 2 (C 1 -C 6 alkyl), amino(C 1 -C 6 alkoxy), amino(C 1 -C 6 alkyl)- or hydroxy(C 1 -C 6 alkyl)-; and,
R 7 and R 8 are each independently H, C 1 -C 6 alkyl, C 1 -C 4 alkoxy(C 1 -C 6 alkyl) or C 3 -C 8 cycloalkyl, said C 1 -C 6 alkyl is optionally substituted by halo, CN or hydroxy; or, R 7 and R 8 together with the atom bonded thereto form a 5- or 6-membered ring, said ring being optionally substituted by halo, hydroxy, CN, or C 1 -C 6 alkyl.
7. The compound of claim 1 having the structure (Ib):
or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein:
W is H, halo, or is selected from the group consisting of:
A, A′ and A″ are independently O, S, C═O, C—R′, N or N—R″, where R′ and R″ may independently be H, amino, —NR 7 COR 6 , COR 6 , —CONR 7 R 8 , —NHSO 2 (C 1 -C 6 alkyl), C 1 -C 6 alkyl, halo, amino(C 1 -C 6 alkyl)-, C 3 -C 8 cycloalkyl, heteroaryl, heterocyclic, heterocyclic(C 1 -C 6 alk-yl)-, hydroxy(C 1 -C 6 alkyl)-, or hydroxy(halo-C 1 -C 6 alkyl)-, where each said moiety may be present or absent, and is present where the rules of valency permit, subject to the proviso that not more than one of A, A′ and A″ is O, S or C═O; where C 1 -C 6 alkyl is optionally substituted by OH, halo, N(C 1 -C 6 alkyl) and heterocyclic;
R 0 is H, D or C 1 -C 6 alkyl-;
R 5 and R 6 are independently H, halo, amino, —OH, —CO 2 H, —CONH 2 , C 1 -C 6 alkyl, C 1 -C 6 alkoxy-, —hydroxy(C 1 -C 6 alkoxy)-, hydroxy(C 1 -C 6 alkoxy)-, heteroaryl-, heterocyclic-, —SO 2 NH 2 , —NHSO 2 (C 1 -C 6 alkyl), —NHCO(C 1 -C 6 alkyl), —NHCO 2 (C 1 -C 6 alkyl), —SO 2 (C 1 -C 6 alkyl), amino(C 1 -C 6 alkoxy), amino(C 1 -C 6 alkyl)- or hydroxy(C 1 -C 6 alkyl)-; and,
R 7 and R 8 are each independently H, C 1 -C 6 alkyl, C 1 -C 4 alkoxy(C 1 -C 6 alkyl) or C 3 -C 8 cycloalkyl, said C 1 -C 6 alkyl is optionally substituted by halo, CN or hydroxy; or, R 7 and R 8 together with the atom bonded thereto form a 5- or 6-membered ring, said ring being optionally substituted by halo, hydroxy, CN, or C 1 -C 6 alkyl.
8. The compound of claim 1 selected from the group consisting of:
[3-{4-[7-(1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-1-(2,2,2-trifluoroethyl)azetidin-3-yl]acetonitrile;
2,2′-(cis-1-{4-[7-(1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutane-1,3-diyl)diacetonitrile;
[3-{4-[7-(1-methyl-1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-1-(2,2,2-trifluoroethyl)azetidin-3-yl]acetonitrile;
cis-3-(cyanomethyl)-3-(4-{7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)cyclobutanecarbonitrile;
[3-(4-{7-[1-(oxetan-3-yl)-1H-pyrazol-4-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)-1-(2,2,2-trifluoroethyl)azetidin-3-yl]acetonitrile;
[3-(4-{7-[1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)-1-(2,2,2-trifluoroethyl)azetidin-3-yl]acetonitrile;
[trans-1-(4-{7-[3-(hydroxymethyl)-1H-pyrazol-5-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)-3-methoxycyclobutyl]acetonitrile;
[3-{3-[7-(1H-pyrazol-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-1-(2,2,2-trifluoroethyl)azetidin-3-yl]acetonitrile;
[1-(methylsulfonyl)-3-{3-[7-(1H-pyrazol-5-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}azetidin-3-yl]acetonitrile;
[1-(cyclopropylsulfonyl)-3-{3-[7-(1H-pyrazol-5-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}azetidin-3-yl]acetonitrile;
[1-(oxetan-3-ylsulfonyl)-3-{3-[7-(1H-pyrazol-5-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}azetidin-3-yl]acetonitrile;
trans-3-(cyanomethyl)-3-{3-[7-(1H-pyrazol-5-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-{3-[7-(1H-pyrazol-5-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutanecarbonitrile;
2,2′-(cis-1-{3-[7-(1H-pyrazol-5-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutane-1,3-diyl)diacetonitrile;
cis-3-(cyanomethyl)-1-methyl-3-{3-[7-(1H-pyrazol-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutanecarbonitrile;
trans-3-{3-[7-(5-amino-1H-pyrazol-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
[3-{3-[7-(5-methyl-1H-pyrazol-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-1-(2,2,2-trifluoroethyl)azetidin-3-yl]acetonitrile;
trans-3-(cyanomethyl)-3-{3-[7-(5-methyl-1H-pyrazol-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-{3-[7-(5-methyl-1H-pyrazol-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-1-methyl-3-{3-[7-(5-methyl-1H-pyrazol-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutanecarbonitrile;
trans-3-(cyanomethyl)-3-(3-{7-[5-(hydroxymethyl)-1H-pyrazol-3-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-(3-{7-[5-(hydroxymethyl)-1H-pyrazol-3-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)cyclobutanecarbonitrile;
[cis-1-(3-{7-[3-(hydroxymethyl)-1H-pyrazol-5-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)-3-methoxycyclobutyl]acetonitrile;
(cis-1-{3-[7-(5-amino-1H-pyrazol-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-3-methoxycyclobutyl)acetonitrile;
(trans-1-{3-[7-(5-amino-1H-pyrazol-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-3-methoxycyclobutyl)acetonitrile;
trans-3-(cyanomethyl)-3-{3-[7-(1,5-dimethyl-1H-pyrazol-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-{3-[7-(1,5-dimethyl-1H-pyrazol-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-(3-{7-[3-(hydroxymethyl)-1-methyl-1H-pyrazol-5-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-(3-{7-[5-(hydroxymethyl)-1-methyl-1H-pyrazol-3-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)cyclobutanecarbonitrile;
trans-3-{3-[7-(5-amino-1-methyl-1H-pyrazol-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
cis-3-{3-[7-(5-amino-1-methyl-1H-pyrazol-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
cis-3-{3-[7-(5-amino-1-methyl-1H-pyrazol-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-3-(cyanomethyl)-1-methylcyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-{3-[7-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutanecarbonitrile;
trans-3-(cyanomethyl)-3-{3-[7-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutanecarbonitrile;
[3-{3-[7-(1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-1-(2,2,2-trifluoroethyl)azetidin-3-yl]acetonitrile;
[1-(methylsulfonyl)-3-{3-[7-(1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}azetidin-3-yl]acetonitrile;
cis-3-(cyanomethyl)-3-{3-[7-(1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutanecarbonitrile;
trans-3-(cyanomethyl)-3-{3-[7-(1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutanecarbonitrile;
2,2′-(cis-1-{3-[7-(1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutane-1,3-diyl)diacetonitrile;
(cis-3-methoxy-1-{3-[7-(1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutyl)acetonitrile;
cis-3-(cyanomethyl)-1-methyl-3-{3-[7-(1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutanecarbonitrile;
[cis-3-(1H-pyrazol-5-yl)-1-{3-[7-(1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutyl]acetonitrile;
cis-3-(cyanomethyl)-3-{3-[7-(3-methyl-1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutanecarbonitrile;
trans-3-(cyanomethyl)-3-(3-{7-[5-(hydroxymethyl)-1H-pyrazol-4-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-(3-{7-[5-(hydroxymethyl)-1H-pyrazol-4-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)cyclobutanecarbonitrile;
[3-{3-[7-(3-amino-1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-1-(methylsulfonyl)azetidin-3-yl]acetonitrile;
(trans-1-{3-[7-(3-amino-1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-3-methoxycyclobutyl)acetonitrile;
(cis-1-{3-[7-(3-amino-1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-3-methoxycyclobutyl)acetonitrile;
cis-3-{3-[7-(3-amino-1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
trans-3-{3-[7-(3-amino-1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
[3-{3-[7-(1-methyl-1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-1-(2,2,2-trifluoroethyl)azetidin-3-yl]acetonitrile;
2,2′-(3-{3-[7-(1-methyl-1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}azetidine-1,3-diyl)diacetonitrile;
trans-3-(cyanomethyl)-3-{3-[7-(1-methyl-1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-{3-[7-(1-methyl-1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutanecarbonitrile;
[3-{3-[7-(1-methyl-1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-1-(methylsulfonyl)azetidin-3-yl]acetonitrile;
[1-(ethylsulfonyl)-3-{3-[7-(1-methyl-1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}azetidin-3-yl]acetonitrile;
[1-(cyclopropylsulfonyl)-3-{3-[7-(1-methyl-1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}azetidin-3-yl]acetonitrile;
3-(cyanomethyl)-3-{3-[7-(1-methyl-1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}azetidine-1-sulfonamide;
[3-{3-[7-(1-ethyl-1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-1-(2,2,2-trifluoroethyl)azetidin-3-yl]acetonitrile;
cis-3-(cyanomethyl)-3-{3-[7-(1-ethyl-1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutanecarbonitrile;
trans-3-(cyanomethyl)-3-{3-[7-(1-ethyl-1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-[3-(7-{1-[2-(dimethylamino)ethyl]-1H-pyrazol-4-yl}-1,6-naphthyridin-5-yl)-1H-pyrazol-1-yl]cyclobutanecarbonitrile;
[3-(3-{7-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)-1-(2,2,2-trifluoroethyl)azetidin-3-yl]acetonitrile;
[3-(3-{7-[1-(oxetan-3-yl)-1H-pyrazol-4-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)-1-(2,2,2-trifluoroethyl)azetidin-3-yl]acetonitrile;
2,2′-[3-(3-{7-[1-(oxetan-3-yl)-1H-pyrazol-4-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)azetidine-1,3-diyl]diacetonitrile;
[1-(methylsulfonyl)-3-(3-{7-[1-(oxetan-3-yl)-1H-pyrazol-4-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)azetidin-3-yl]acetonitrile;
{1-(methylsulfonyl)-3-[3-(7-{1-[(3S)-tetrahydrofuran-3-yl]-1H-pyrazol-4-yl}-1,6-naphthyridin-5-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile;
{1-(methylsulfonyl)-3-[3-(7-{1-[(3R)-tetrahydrofuran-3-yl]-1H-pyrazol-4-yl}-1,6-naphthyridin-5-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile;
[3-(3-{7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)-1-(methylsulfonyl)azetidin-3-yl]acetonitrile;
trans-3-(cyanomethyl)-3-(3-{7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-(3-{7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)cyclobutanecarbonitrile;
[3-(3-{7-[1-(1-chloro-3-hydroxypropan-2-yl)-1H-pyrazol-4-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)-1-(methylsulfonyl)azetidin-3-yl]acetonitrile;
[1-(methylsulfonyl)-3-(3-{7-[1-(oxetan-3-ylmethyl)-1H-pyrazol-4-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)azetidin-3-yl]acetonitrile;
trans-3-(cyanomethyl)-3-(3-{7-[3-(hydroxymethyl)-1-methyl-1H-pyrazol-4-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)cyclobutanecarbonitrile;
trans-3-(cyanomethyl)-3-(3-{7-[5-(hydroxymethyl)-1-methyl-1H-pyrazol-4-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)cyclobutanecarbonitrile;
[3-{3-[7-(3-amino-1-methyl-1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-1-(methylsulfonyl)azetidin-3-yl]acetonitrile;
trans-3-{3-[7-(3-amino-1-methyl-1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
cis-3-{3-[7-(3-amino-1-methyl-1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
trans-3-{3-[7-(5-amino-1-methyl-1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
cis-3-{3-[7-(5-amino-1-methyl-1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-(3-{7-[3-(hydroxymethyl)-1,2-oxazol-5-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)cyclobutanecarbonitrile;
[3-{3-[7-(1H-pyrrolo[3,2-b]pyridin-6-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-1-(2,2,2-trifluoroethyl)azetidin-3-yl]acetonitrile;
[1-(methylsulfonyl)-3-{3-[7-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}azetidin-3-yl]acetonitrile;
[1-(methylsulfonyl)-3-{3-[7-(pyrazolo[1,5-a]pyridin-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}azetidin-3-yl]acetonitrile;
[3-{3-[7-(imidazo[1,2-a]pyridin-7-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-1-(methylsulfonyl)azetidin-3-yl]acetonitrile;
[1-(methylsulfonyl)-3-{3-[7-(1H-pyrazolo[4,3-b]pyridin-6-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}azetidin-3-yl]acetonitrile;
[1-(methylsulfonyl)-3-{3-[7-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}azetidin-3-yl]acetonitrile;
[3-{3-[7-(pyridin-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-1-(2,2,2-trifluoroethyl)azetidin-3-yl]acetonitrile;
[3-{3-[7-(2-methylpyridin-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-1-(methylsulfonyl)azetidin-3-yl]acetonitrile;
[3-{3-[7-(6-hydroxypyridin-2-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-1-(methylsulfonyl)azetidin-3-yl]acetonitrile;
cis-3-(cyanomethyl)-3-{3-[7-(6-hydroxypyridin-2-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutanecarbonitrile;
[3-{3-[7-(6-hydroxypyridin-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-1-(2,2,2-trifluoroethyl)azetidin-3-yl]acetonitrile;
[3-{3-[7-(6-aminopyridin-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-1-(methylsulfonyl)azetidin-3-yl]acetonitrile;
cis-3-{3-[7-(6-aminopyridin-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
trans-3-{3-[7-(6-aminopyridin-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
[3-{3-[7-(2-aminopyridin-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-1-(2,2,2-trifluoroethyl)azetidin-3-yl]acetonitrile;
cis-3-{3-[7-(2-aminopyridin-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
trans-3-{3-[7-(2-aminopyridin-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
cis-3-{3-[7-(2-aminopyridin-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-3-(cyanomethyl)-1-methylcyclobutanecarbonitrile;
[3-(3-{7-[6-(dimethylamino)pyridin-3-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)-1-(methylsulfonyl)azetidin-3-yl]acetonitrile;
N-[5-(5-{1-[3-(cyanomethyl)-1-(methylsulfonyl)azetidin-3-yl]-1H-pyrazol-3-yl}-1,6-naphthyridin-7-yl)pyridin-2-yl]methanesulfonamide;
cis-3-(cyanomethyl)-3-(3-{7-[6-(methylsulfonyl)pyridin-3-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)cyclobutanecarbonitrile;
5-(5-{1-[cis-3-cyano-1-(cyanomethyl)cyclobutyl]-1H-pyrazol-3-yl}-1,6-naphthyridin-7-yl)pyridine-2-sulfonamide;
cis-3-(cyanomethyl)-3-(3-{7-[2-(hydroxymethyl)pyridin-4-yl]-1,6-naphthyridin-5-yl}-1H-pyrazol-1-yl)cyclobutanecarbonitrile;
4-(5-{1-[cis-3-cyano-1-(cyanomethyl)cyclobutyl]-1H-pyrazol-3-yl}-1,6-naphthyridin-7-yl)pyridine-2-carboxamide;
[3-{3-[7-(2-amino-6-methylpyridin-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-1-(methylsulfonyl)azetidin-3-yl]acetonitrile;
cis-3-{3-[7-(2-amino-6-methylpyridin-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
cis-3-{3-[7-(5-amino-6-methoxypyridin-2-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
3-amino-6-(5-{1-[cis-3-cyano-1-(cyanomethyl)cyclobutyl]-1H-pyrazol-3-yl}-1,6-naphthyridin-7-yl)pyridine-2-carboxamide;
3-amino-6-(5-{1-[trans-3-cyano-1-(cyanomethyl)cyclobutyl]-1H-pyrazol-3-yl}-1,6-naphthyridin-7-yl)pyridine-2-carboxamide;
[3-{3-[7-(2,6-diaminopyridin-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-1-(methylsulfonyl)azetidin-3-yl]acetonitrile;
cis-3-{3-[7-(6-aminopyridazin-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
4-(5-{1-[trans-3-cyano-1-(cyanomethyl)cyclobutyl]-1H-pyrazol-3-yl}-1,6-naphthyridin-7-yl)pyrimidine-2-carboxamide;
[1-(methylsulfonyl)-3-{3-[7-(6-oxo-1,6-dihydropyridin-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}azetidin-3-yl]acetonitrile;
[1-(cyclopropylsulfonyl)-3-{3-[7-(6-oxo-1,6-dihydropyridin-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}azetidin-3-yl]acetonitrile;
(cis-3-methoxy-1-{3-[7-(6-oxo-1,6-dihydropyridin-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutyl)acetonitrile;
[3-{3-[7-(1-ethyl-6-oxo-1,6-dihydropyridin-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-1-(methylsulfonyl)azetidin-3-yl]acetonitrile;
[3-{3-[7-(2-hydroxyphenyI)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-1-(methylsulfonyl)azetidin-3-yl]acetonitrile;
[3-{3-[7-(4-hydroxyphenyl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-1-(methylsulfonyl)azetidin-3-yl]acetonitrile;
N-[4-(5-{1-[cis-3-cyano-1-(cyanomethyl)cyclobutyl]-1H-pyrazol-3-yl}-1,6-naphthyridin-7-yl)phenyl]methanesulfonamide;
N-[4-(5-{1-[trans-3-cyano-1-(cyanomethyl)cyclobutyl]-1H-pyrazol-3-yl}-1,6-naphthyridin-7-yl)phenyl]methanesulfonamide;
[3-{3-[7-(4-fluoro-2-hydroxyphenyl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-1-(methylsulfonyl)azetidin-3-yl]acetonitrile;
[3-{3-[7-(3-fluoro-4-hydroxyphenyl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}-1-(methylsulfonyl)azetidin-3-yl]acetonitrile;
cis-3-(cyanomethyl)-3-{5-methyl-3-[7-(1H-pyrazol-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutanecarbonitrile;
trans-3-(cyanomethyl)-3-{5-methyl-3-[7-(1H-pyrazol-3-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutanecarbonitrile;
trans-3-{3-[7-(5-amino-1-methyl-1H-pyrazol-3-yl)-1,6-naphthyridin-5-yl]-5-methyl-1H-pyrazol-1-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
cis-3-{3-[7-(5-amino-1-methyl-1H-pyrazol-3-yl)-1,6-naphthyridin-5-yl]-5-methyl-1H-pyrazol-1-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
trans-3-(cyanomethyl)-3-{5-methyl-3-[7-(1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-{5-methyl-3-[7-(1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-pyrazol-1-yl}cyclobutanecarbonitrile;
trans-3-{3-[7-(5-amino-1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-5-methyl-1H-pyrazol-1-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
[3-{4-[7-(1-methyl-1H-pyrazol-4-yl)-1,6-naphthyridin-5-yl]-1H-1,2,3-triazol-1-yl}-1-(2,2,2-trifluoroethyl)azetidin-3-yl]acetonitrile;
[1-(methylsulfonyl)-3-{4-[7-(1H-pyrazol-3-yl)-1,6-naphthyridin-5-yl]-2H-1,2,3-triazol-2-yl}azetidin-3-yl]acetonitrile;
2,2′-(3-{4-[7-(1-methyl-1H-pyrazol-4-yl)quinolin-5-yl]-1H-pyrazol-1-yl}azetidine-1,3-diyl)diacetonitrile;
[3-{4-[7-(1H-pyrazol-3-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}-1-(2,2,2-trifluoroethyl)azetidin-3-yl]acetonitrile;
[1-(methylsulfonyl)-3-{4-[7-(1H-pyrazol-3-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}azetidin-3-yl]acetonitrile;
[1-(cyclopropylsulfonyl)-3-{4-[7-(1H-pyrazol-3-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}azetidin-3-yl]acetonitrile;
3-(cyanomethyl)-3-{4-[7-(1H-pyrazol-3-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}azetidine-1-sulfonamide;
[1-(oxetan-3-ylsulfonyl)-3-{4-[7-(1H-pyrazol-5-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}azetidin-3-yl]acetonitrile;
trans-3-(cyanomethyl)-3-{4-[7-(1H-pyrazol-3-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-{4-[7-(1H-pyrazol-3-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}cyclobutanecarbonitrile;
(cis-3-methoxy-1-{4-[7-(1H-pyrazol-3-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}cyclobutyl)acetonitrile;
(trans-3-methoxy-1-{4-[7-(1H-pyrazol-3-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}cyclobutyl)acetonitrile;
trans-3-{4-[7-(5-amino-1H-pyrazol-3-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
cis-3-{4-[7-(5-amino-1H-pyrazol-3-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
trans-3-(cyanomethyl)-3-(4-{7-[5-(hydroxymethyl)-1H-pyrazol-3-yl]quinolin-5-yl}-2H-1,2,3-triazol-2-yl)cyclobutanecarbonitrile;
trans-3-(cyanomethyl)-3-(4-{7-[5-(hydroxymethyl)-1-methyl-1H-pyrazol-3-yl]quinolin-5-yl}-2H-1,2,3-triazol-2-yl)cyclobutanecarbonitrile;
[3-{4-[7-(1-methyl-1H-pyrazol-3-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}-1-(methylsulfonyl)azetidin-3-yl]acetonitrile;
trans-3-(cyanomethyl)-3-{4-[7-(1-methyl-1H-pyrazol-3-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-{4-[7-(1-methyl-1H-pyrazol-3-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}cyclobutanecarbonitrile;
[1-(methylsulfonyl)-3-{4-[7-(1H-pyrazol-4-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}azetidin-3-yl]acetonitrile;
trans-3-(cyanomethyl)-3-{4-[7-(1H-pyrazol-4-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-{4-[7-(1H-pyrazol-4-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-(4-{7-[3-(hydroxymethyl)-1H-pyrazol-4-yl]quinolin-5-yl}-2H-1,2,3-triazol-2-yl)cyclobutanecarbonitrile;
trans-3-{4-[7-(5-amino-1H-pyrazol-4-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
cis-3-{4-[7-(5-amino-1H-pyrazol-4-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
trans-3-(cyanomethyl)-3-{4-[7-(1-methyl-1H-pyrazol-4-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-{4-[7-(1-methyl-1H-pyrazol-4-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}cyclobutanecarbonitrile;
trans-3-(cyanomethyl)-3-(4-{7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]quinolin-5-yl}-2H-1,2,3-triazol-2-yl)cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-(4-{7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]quinolin-5-yl}-2H-1,2,3-triazol-2-yl)cyclobutanecarbonitrile;
cis-3-{4-[7-(3-amino-1-methyl-1H-pyrazol-4-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
trans-3-{4-[7-(3-amino-1-methyl-1H-pyrazol-4-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-{4-[7-(2-methyl-1H-imidazol-4-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}cyclobutanecarbonitrile;
trans-3-(cyanomethyl)-3-{4-[7-(2-methyl-1H-imidazol-4-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}cyclobutanecarbonitrile;
trans-3-(cyanomethyl)-3-{4-[7-(1-methyl-1H-1,2,3-triazol-4-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-(4-{7-[4-(hydroxymethyl)-1,3-thiazol-2-yl]quinolin-5-yl}-2H-1,2,3-triazol-2-yl)cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-{4-[7-(pyridin-2-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-{4-[7-(5-fluoropyridin-2-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}cyclobutanecarbonitrile;
6-(5-{2-[trans-3-cyano-1-(cyanomethyl)cyclobutyl]-2H-1,2,3-triazol-4-yl}quinolin-7-yl)pyridine-2-carboxamide;
6-(5-{2-[cis-3-cyano-1-(cyanomethyl)cyclobutyl]-2H-1,2,3-triazol-4-yl}quinolin-7-yl)pyridine-2-carboxamide;
6-(5-{2-[cis-3-cyano-1-(cyanomethyl)cyclobutyl]-2H-1,2,3-triazol-4-yl}quinolin-7-yl)pyridine-3-carboxamide;
cis-3-{4-[7-(6-aminopyridin-2-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
cis-3-{4-[7-(5-aminopyridin-2-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
trans-3-{4-[7-(5-aminopyridin-2-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
cis-3-{4-[7-(6-aminopyridin-3-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-(4-{7-[5-(methylsulfonyl)pyridin-2-yl]quinolin-5-yl}-2H-1,2,3-triazol-2-yl)cyclobutanecarbonitrile;
6-(5-{2-[cis-3-cyano-1-(cyanomethyl)cyclobutyl]-2H-1,2,3-triazol-4-yl}quinolin-7-yl)pyridine-2-carboxylic acid;
N-[6-(5-{2-[cis-3-cyano-1-(cyanomethyl)cyclobutyl]-2H-1,2,3-triazol-4-yl}quinolin-7-yl)pyridin-2-yl]methanesulfonamide;
N-[6-(5-{2-[cis-3-cyano-1-(cyanomethyl)cyclobutyl]-2H-1,2,3-triazol-4-yl}quinolin-7-yl)pyridin-3-yl]methanesulfonamide;
N-[6-(5-{2-[trans-3-cyano-1-(cyanomethyl)cyclobutyl]-2H-1,2,3-triazol-4-yl}quinolin-7-yl)pyridin-3-yl]methanesulfonamide;
N-[6-(5-{2-[trans-3-cyano-1-(cyanomethyl)cyclobutyl]-2H-1,2,3-triazol-4-yl}quinolin-7-yl)pyridin-2-yl]acetamide;
N-[6-(5-{2-[cis-3-cyano-1-(cyanomethyl)cyclobutyl]-2H-1,2,3-triazol-4-yl}quinolin-7-yl)pyridin-2-yl]acetamide;
cis-3-(cyanomethyl)-3-(4-{7-[5-(2-hydroxyethyl)-6-methylpyridin-2-yl]quinolin-5-yl}-2H-1,2,3-triazol-2-yl)cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-{4-[7-(5-hydroxy-6-methylpyridin-2-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}cyclobutanecarbonitrile;
cis-3-{4-[7-(5-amino-6-methoxypyridin-2-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
trans-3-{4-[7-(5-amino-6-methoxypyridin-2-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
cis-3-{4-[7-(6-aminopyridazin-3-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}-3-(cyanomethyl)cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-{4-[7-(2-oxo-1,2-dihydropyridin-4-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}cyclobutanecarbonitrile;
cis-3-(cyanomethyl)-3-{4-[7-(2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)quinolin-5-yl]-2H-1,2,3-triazol-2-yl}cyclobutanecarbonitrile;
or, a pharmaceutically acceptable salt thereof.
9. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt, and a pharmaceutically acceptable excipient.
10. A method of treating a disease or condition selected from systemic lupus erythematous, lupus nephritis, discoid lupus, cutaneous lupus, central nervous system lupus, rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, asthma, allergic asthma, Type I diabetes, polymyositis, dermatomyositis, type I interferonopathies including Aicardi-Goutières syndrome and other mendelian diseases of overexpression of type I interferon, multiple sclerosis, primary progressive multiple sclerosis, relapsing remitting multiple sclerosis, primary biliary cirrhosis also known as primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, psoriasis, dermatomyositis, scleroderma, atopic dermatitis, vitiligo, alopecia areata, spondylopathy, ankylosing spondylitis, Alzheimer's disease, neuro-inflammation comprising administering to a subject suffering from said disease condition a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt.